《2022年国际立场声明: 人血白蛋白在肝硬化相关并发症治疗中的应用》摘译

  • 打印
  • 收藏
收藏成功


打开文本图片集

摘要:近期,来自19个国家的33名具有肝硬化相关并发症管理专业知识的研究人员经过三轮德尔菲法提出了12项有关人血白蛋白在肝硬化相关并发症治疗中应用的国际立场声明。本文对该部国际立场声明的主要内容进行中文摘译。关键词:肝硬化; 血清白蛋白, 人; 共识

An excerpt of use of albumin infusion for cirrhosis-related complications: an international position statement in 2022

BAI Zhaohui YANG Yongping YANG Li QI Xingshun(1. Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China; 2. Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China; 3. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China)

Corresponding author:QI Xingshun, xingshunqi@126.com (ORCID:0000-0002-9448-6739)

Abstract:Recently, 33 investigators from 19 countries with expertise in managing cirrhosis-related complications have proposed 12 international position statements regarding the use of human albumin infusion for cirrhosis-related complications after a three-round Delphi consensus process. This article gives an excerpt of the main contents of this international position statement in Chinese language.

Key words:Liver Cirrhosis; Serum Albumin, Human; Consensus

肝硬化是威胁人类生命健康的重大疾病,其在全世界范围内广泛流行并给各国造成了沉重的医疗负担。(剩余1674字)

目录
monitor